TNDM
Bearish signalScored 2026-10-18 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Tandem Diabetes Care, Inc.
- Nom
- Tandem Diabetes Care, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $1.2B
- Employés
- 2,500
- PDG
- John F. Sheridan
- Site web
- https://www.tandemdiabetes.com
- Marché
- BBNXDXCMGUTSMMEDMMEDVMNKD
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-18 17:07:39
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-29 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-03 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-09-22 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-03-19 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2025-03-04 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2024-08-05 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-18 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
TNDM presents a deeply concerning financial profile with a liquidity score of 35 and a fundamental trend score of 15, reflecting persistent net losses, negative free cash flow, and unsustainable leverage.
The first sentence of the analysis written for TNDM on 2026-10-18 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 2.55 · operating margin -7.7% — readings disagree
Recent news
- 2026-10-14 Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM) Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Taiwan Semiconductor Manufacturing stock on September 22nd. The trade occurred in the Representative''s "150 MAIN STREET TRUST > BANK OF
- 2026-10-09 Is it the Right Time to Hold TNDM Stock in Your Portfolio? Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.
- 2026-10-01 Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026 SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2026 financial and operating results. A live webcast of the call will be available on Tandem Diab.
- 2026-09-30 Head to Head Contrast: Solventum (NYSE:SOLV) & Tandem Diabetes Care (NASDAQ:TNDM) Tandem Diabetes Care (NASDAQ: TNDM - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability. Analyst Ratings This is a breakdown of recent
- 2026-09-28 Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets [url="]Tandem Diabetes Care, Inc[/url]. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world''
- 2026-09-28 Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets MILAN--(BUSINESS WIRE)---- $TNDM #T2D--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.
- 2026-09-17 Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock? Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 2026-09-10 Is Tandem Diabetes Care Inc (TNDM) a Bargain After 4.2% Drop? GF Value Says Undervalued On September 10, 2026, Tandem Diabetes Care Inc (TNDM) shares fell 4.2% to a current price of $18.31. The stock has experienced notable volatility, trading betw
- 2026-09-09 Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now TNDM''s expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
- 2026-08-21 Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 52.3% | 52.1% | 49.2% | 51.5% | 53.5% | |
| Ebit Margin | -19.0% | -10.6% | -28.4% | -11.1% | 2.9% | |
| Ebitda Margin | -17.2% | -8.8% | -26.3% | -9.3% | 4.8% | |
| Operating Profit Margin | -7.7% | -10.5% | -31.2% | -11.6% | 3.2% | |
| Pretax Profit Margin | -19.7% | -9.8% | -29.5% | -11.6% | 2.3% | |
| Continuous Operations Profit Margin | -20.2% | -10.2% | -29.8% | -11.8% | 2.2% | |
| Net Profit Margin | -20.2% | -10.2% | -29.8% | -11.8% | 2.2% | |
| Bottom Line Profit Margin | -20.2% | -10.2% | -29.8% | -11.8% | 2.2% | |
| Current Ratio | 2.547 | 2.933 | 3.831 | 5.142 | 6.155 | |
| Quick Ratio | 2.016 | 2.327 | 3.022 | 4.470 | 5.635 | |
| Solvency Ratio | -0.258 | -0.113 | -0.324 | -0.131 | 0.062 | |
| Cash Ratio | 0.373 | 0.280 | 0.301 | 1.044 | 0.540 | |
| Price To Earnings Ratio | -7.230 | -24.503 | -8.624 | -30.578 | 602.080 | |
| Price To Earnings Growth Ratio | -0.068 | 0.429 | -0.065 | 0.044 | -4.163 | |
| Forward Price To Earnings Growth Ratio | -0.068 | 0.429 | -0.065 | 0.044 | -4.163 | |
| Price To Earnings Diluted Ratio | -7.230 | -24.503 | -8.624 | -30.578 | 627.167 | |
| Price To Earnings Diluted Growth Ratio | -0.068 | 0.429 | -0.065 | 0.043 | -4.390 | |
| Price To Book Ratio | 9.531 | 8.961 | 6.121 | 6.554 | 21.894 | |
| Price To Sales Ratio | 1.457 | 2.507 | 2.568 | 3.599 | 13.493 | |
| Price To Free Cash Flow Ratio | -49.847 | 472.075 | -32.753 | 176.169 | 107.945 | |
| Price To Operating Cash Flow Ratio | -152.137 | 97.319 | -60.351 | 57.137 | 85.155 | |
| Debt To Assets Ratio | 0.504 | 0.489 | 0.436 | 0.399 | 0.348 | |
| Debt To Equity Ratio | 2.864 | 1.800 | 1.325 | 0.954 | 0.727 | |
| Debt To Capital Ratio | 0.741 | 0.643 | 0.570 | 0.488 | 0.421 | |
| Long Term Debt To Capital Ratio | 0.666 | 0.540 | 0.476 | 0.392 | 0.394 | |
| Financial Leverage Ratio | 5.678 | 3.678 | 3.038 | 2.393 | 2.090 | |
| Working Capital Turnover Ratio | 2.380 | 1.825 | 1.209 | 1.175 | 1.159 | |
| Operating Cash Flow Ratio | -0.040 | 0.098 | -0.163 | 0.305 | 0.845 | |
| Operating Cash Flow Sales Ratio | -0.010 | 0.026 | -0.043 | 0.063 | 0.158 | |
| Free Cash Flow Operating Cash Flow Ratio | 3.052 | 0.206 | 1.843 | 0.324 | 0.789 | |
| Debt Service Coverage Ratio | -22.655 | -1.806 | -20.119 | -12.234 | 5.583 | |
| Interest Coverage Ratio | -9.880 | -13.368 | -23.601 | -14.956 | 3.750 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.596 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.022 | 0.051 | -0.077 | 0.120 | 0.354 | |
| Capital Expenditure Coverage Ratio | -0.487 | 1.260 | -1.187 | 1.480 | 4.736 | |
| Dividend Paid And Capex Coverage Ratio | -0.487 | 1.260 | -1.187 | 1.480 | 4.736 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -10.491 | -33.405 | -11.588 | -42.188 | 285.571 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 52.3% | ▲0.2% | ▲0.6% |
| Ebit Margin | -19.0% | ▼-8.4% | ▼-5.7% |
| Ebitda Margin | -17.2% | ▼-8.4% | ▼-5.9% |
| Operating Profit Margin | -7.7% | ▲2.8% | ▲3.9% |
| Pretax Profit Margin | -19.7% | ▼-10.0% | ▼-6.1% |
| Continuous Operations Profit Margin | -20.2% | ▼-10.0% | ▼-6.2% |
| Net Profit Margin | -20.2% | ▼-10.0% | ▼-6.2% |
| Bottom Line Profit Margin | -20.2% | ▼-10.0% | ▼-6.2% |
| Current Ratio | 2.547 | ▼-0.386 | ▼-1.575 |
| Quick Ratio | 2.016 | ▼-0.311 | ▼-1.478 |
| Solvency Ratio | -0.258 | ▼-0.145 | ▼-0.105 |
| Cash Ratio | 0.373 | ▲0.093 | ▼-0.134 |
| Price To Earnings Ratio | -7.230 | ▲17.273 | ▼-113.459 |
| Price To Earnings Growth Ratio | -0.068 | ▼-0.496 | ▲0.697 |
| Forward Price To Earnings Growth Ratio | -0.068 | ▼-0.496 | ▲0.697 |
| Price To Earnings Diluted Ratio | -7.230 | ▲17.273 | ▼-118.476 |
| Price To Earnings Diluted Growth Ratio | -0.068 | ▼-0.496 | ▲0.743 |
| Price To Book Ratio | 9.531 | ▲0.570 | ▼-1.081 |
| Price To Sales Ratio | 1.457 | ▼-1.050 | ▼-3.267 |
| Price To Free Cash Flow Ratio | -49.847 | ▼-521.923 | ▼-184.565 |
| Price To Operating Cash Flow Ratio | -152.137 | ▼-249.456 | ▼-157.561 |
| Debt To Assets Ratio | 0.504 | ▲0.015 | ▲0.069 |
| Debt To Equity Ratio | 2.864 | ▲1.065 | ▲1.330 |
| Debt To Capital Ratio | 0.741 | ▲0.098 | ▲0.169 |
| Long Term Debt To Capital Ratio | 0.666 | ▲0.127 | ▲0.173 |
| Financial Leverage Ratio | 5.678 | ▲2.000 | ▲2.303 |
| Working Capital Turnover Ratio | 2.380 | ▲0.554 | ▲0.830 |
| Operating Cash Flow Ratio | -0.040 | ▼-0.138 | ▼-0.249 |
| Operating Cash Flow Sales Ratio | -0.010 | ▼-0.035 | ▼-0.049 |
| Free Cash Flow Operating Cash Flow Ratio | 3.052 | ▲2.846 | ▲1.809 |
| Debt Service Coverage Ratio | -22.655 | ▼-20.850 | ▼-12.409 |
| Interest Coverage Ratio | -9.880 | ▲3.488 | ▲1.731 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-0.596 | ▼-0.119 |
| Operating Cash Flow Coverage Ratio | -0.022 | ▼-0.073 | ▼-0.107 |
| Capital Expenditure Coverage Ratio | -0.487 | ▼-1.747 | ▼-1.648 |
| Dividend Paid And Capex Coverage Ratio | -0.487 | ▼-1.747 | ▼-1.648 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -10.491 | ▲22.914 | ▼-48.071 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.48B | $2.36B | $1.92B | $2.88B | $9.48B | |
| Enterprise value | $1.83B | $2.76B | $2.28B | $3.13B | $9.73B | |
| EV / Sales | 1.81x | 2.94x | 3.04x | 3.91x | 13.84x | |
| EV / Op. cash flow | -188.54x | 114.01x | -71.57x | 62.04x | 87.34x | |
| EV / Free cash flow | -61.77x | 553.04x | -38.84x | 191.28x | 110.72x | |
| EV / EBITDA | -10.49x | -33.41x | -11.59x | -42.19x | 285.57x | |
| Net debt / EBITDA | -2.02x | -4.89x | -1.82x | -3.33x | 7.15x | |
| Current ratio | 2.55x | 2.93x | 3.83x | 5.14x | 6.16x | |
| Income quality | 0.05x | -0.25x | 0.14x | -0.53x | 7.15x | |
| Graham number | — | — | — | — | $6 | |
| Graham net-net | -$4 | -$2 | -$0 | $2 | $4 | |
| Tax burden | 102.2% | 104.5% | 101.1% | 101.9% | 97.9% | |
| Interest burden | 104.1% | 92.5% | 103.8% | 104.9% | 78.7% | |
| Working capital | $375.4M | $477.4M | $552.7M | $684.7M | $679.7M | |
| Invested capital | $555.2M | $641.8M | $719.8M | $868.5M | $764.2M | |
| Return on assets | -23.2% | -9.9% | -23.4% | -9.0% | 1.7% | |
| Operating ROA | -8.5% | -10.3% | -23.3% | -9.5% | 2.8% | |
| Return on tangible assets | -23.2% | -9.9% | -23.4% | -9.0% | 1.7% | |
| Return on equity | -131.9% | -36.5% | -71.0% | -21.5% | 3.6% | |
| Return on invested capital | -11.9% | -12.7% | -30.1% | -10.3% | 2.8% | |
| Return on capital employed | -12.2% | -13.8% | -30.8% | -10.5% | 2.9% | |
| Earnings yield | -13.8% | -4.1% | -11.6% | -3.3% | 0.2% | |
| Free cash flow yield | -2.0% | 0.2% | -3.1% | 0.6% | 0.9% | |
| Capex / Op. cash flow | -205.2% | 79.4% | -84.3% | 67.6% | 21.1% | |
| Capex / Depreciation | 112.9% | 115.8% | 170.6% | 237.9% | 169.8% | |
| Capex / Sales | 2.0% | 2.0% | 3.6% | 4.3% | 3.3% | |
| SG&A / Sales | 42.8% | 41.5% | 47.1% | 41.9% | 37.2% | |
| R&D / Sales | 17.2% | 21.2% | 33.2% | 21.2% | 13.1% | |
| Stock comp / Sales | 9.1% | 10.8% | 11.8% | 10.6% | 8.6% | |
| Intangibles / Total assets | 0.0% | 0.1% | 0.3% | 0.4% | 0.7% | |
| Days sales outstanding | 60d | 44d | 52d | 52d | 58d | |
| Days payables outstanding | 36d | 36d | 48d | 52d | 31d | |
| Operating cycle | 157d | 166d | 203d | 157d | 134d | |
| Cash conversion cycle | 121d | 129d | 156d | 104d | 103d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years